Literature DB >> 15860464

Mutation screening and association study of the neprilysin gene in sporadic Alzheimer's disease in Chinese persons.

Jiajun Shi1, Sizhong Zhang, Mouni Tang, Cui Ma, Jinghua Zhao, Tao Li, Xiehe Liu, Yan Sun, Yangbo Guo, Haiying Han, Yongxin Ma, Zhenhuan Zhao.   

Abstract

Neprilysin has been reported to be a major beta-amyloid peptide (Abeta)-degrading enzyme. The decreased expression and activity of it may contribute to the development of Alzheimer's disease by promoting the accumulation of Abeta. We used denaturing high-performance liquid chromatography to screen the neprilysin gene (NEP) for single nucleotide polymorphisms (SNPs) in 257 Chinese sporadic Alzheimer's disease patients and 242 cognitive normal controls. As a result, eight novel and one known SNP were identified. Three of them, -204G-->C in the promoter region, IVS17-294C-->T, and IVS22+36C-->A showed a significant association with Alzheimer's disease (p = .006,.017, and.003, respectively). Subsequent haplotype analysis provided further evidence of the association (global p < .0001 for the three SNPs mentioned above, and global p < .01 for the eight SNPs with rare allele frequency > 1%). These findings indicate that genetic variations within or extremely close to NEP might influence the susceptibility to Alzheimer's disease in Chinese persons.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15860464     DOI: 10.1093/gerona/60.3.301

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  9 in total

Review 1.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

Review 2.  Long-term neprilysin inhibition - implications for ARNIs.

Authors:  Duncan J Campbell
Journal:  Nat Rev Cardiol       Date:  2016-12-15       Impact factor: 32.419

3.  Evaluation of neprilysin sequence variation in relation to CSF β-Amyloid levels and Alzheimer disease risk.

Authors:  Mia E Blomqvist; Shane McCarthy; Kaj Blennow; Björn Andersson; Jonathan A Prince
Journal:  Int J Mol Epidemiol Genet       Date:  2010-10-15

4.  Genetic variation in MME in relation to neprilysin protein and enzyme activity, Aβ levels, and Alzheimer's disease risk.

Authors:  Scott Miners; Zoë van Helmond; Rachel Barker; Peter A Passmore; Janet A Johnston; Stephen Todd; Bernadette M McGuinness; Francesco Panza; Davide Seripa; Vincenzo Solfrizzi; Seth Love; Jonathan A Prince; Patrick G Kehoe
Journal:  Int J Mol Epidemiol Genet       Date:  2012-02-05

Review 5.  Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.

Authors:  J Steven Jacobsen; Peter Reinhart; Menelas N Pangalos
Journal:  NeuroRx       Date:  2005-10

6.  Neprilysin Confers Genetic Susceptibility to Alzheimer's Disease in Han Chinese.

Authors:  Hui-Zhen Wang; Rui Bi; Deng-Feng Zhang; Guo-Dong Li; Xiao-Hong Ma; Yiru Fang; Tao Li; Chen Zhang; Yong-Gang Yao
Journal:  Mol Neurobiol       Date:  2015-09-11       Impact factor: 5.590

7.  beta-Amyloid degradation and Alzheimer's disease.

Authors:  Deng-Shun Wang; Dennis W Dickson; James S Malter
Journal:  J Biomed Biotechnol       Date:  2006

Review 8.  Gene therapy in Alzheimer's disease - potential for disease modification.

Authors:  Per Nilsson; Nobuhisa Iwata; Shin-ichi Muramatsu; Lars O Tjernberg; Bengt Winblad; Takaomi C Saido
Journal:  J Cell Mol Med       Date:  2010-02-16       Impact factor: 5.310

9.  Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice.

Authors:  Brian Spencer; Robert A Marr; Edward Rockenstein; Leslie Crews; Anthony Adame; Rewati Potkar; Christina Patrick; Fred H Gage; Inder M Verma; Eliezer Masliah
Journal:  BMC Neurosci       Date:  2008-11-12       Impact factor: 3.288

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.